Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

As part of the 10th Mediterranean Neuroscience Society Conference, we are excited to present this new collection of articles ...

Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, ...

Research and Development (R&D) Expenses: R&D expenses decreased to $5.8 million for the three months ended March 31, 2025, ...

High-ranking OpenAI employees have met with the FDA multiple times in recent weeks to discuss AI and a project called cderGPT ...

An advocate for cancer patients has said that patients will "die waiting" for cancer treatments in Ireland after a study ...

In a precedential decision issued May 6, 2025, the Federal Circuit reversed in part and vacated in part a Delaware district ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

The product, available in 200 mg, 400 mg, 600 mg, and 800 mg strengths, is the generic equivalent of Sumitomo Pharma ...